Seagen Inc.

Delisted

CIK 1060736fmd_1DCSRTXAXVYP9FRPE8N7RKC7EKManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard

Coverage: Jan 01, 2009 to Sep 30, 2023, 56 periods

Income Statement · Annual · Millions · USD
Line item	FY2013	FY2014	FY2015	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022
Total revenues	269	287	337	418	482	655	917	2,176	1,574	1,962
Cost of revenue	14	18	24	28	35	88	44	218	312	410
Gross profit	256	269	312	390	447	566	873	1,958	1,263	1,552
Research and development	219	231	295	379	457	565	719	827	1,229	1,344
Selling, general and administrative	92	104	126	139	167	261	374	534	716	821
Operating income	(63)	(77)	(121)	(143)	(196)	(260)	(221)	597	(682)	(613)
Income before taxes	–	(76)	(120)	(140)	(159)	(246)	(159)	616	(676)	(602)
Income tax expense	–	–	0	0	(33)	(24)	0	2	(1)	8
Net income from continuing operations	–	–	(120)	(140)	(126)	(223)	(159)	614	(674)	(610)
Net income	(63)	(76)	(120)	(140)	(126)	(223)	(159)	614	(674)	(610)